Company Information


Agenus is an immuno-oncology company focused on the discovery and development of potentially revolutionary new treatments that leverage the body’s immune system to fight cancer and infectious diseases. Agenus has established a highly integrated approach to validate targets of interest, identify therapeutically relevant biomarkers, engineer highly differentiated therapies, and explore novel immunotherapy combinations. The company supports discovery and development efforts with wholly-owned, advanced clinical and manufacturing capabilities and pursues strategic partnerships as means of accelerating development timelines. The company currently has active collaborations with several leaders in the oncology field, including Bristol Myers Squibb, Merck, Gilead and Incyte. Through its subsidiaries, MiNK therapeutics and SaponiQx, Agenus is pursuing allogeneic cell therapies and vaccine adjuvants, respectively.

Press Releases
Nov 16, 2022
LEXINGTON, Mass., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo Armen, Chairman and CEO of Agenus, and Dr. Steven O’Day, Chief Medical Officer, will participate in a

btn News

SEC Filings

Form Description Filing date View

Written public communication relating to an issuer or third party tender offer


Withdrawal of registration statement filed under the Securities Act


Data provided by Kaleidoscope.

btn SEC

Events and Presentations

btn Events